Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07473128 · ClinicalTrials.gov registry record · Phase 3
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
A Phase 3 study, sponsored by Pharmacosmos A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT07473128 is a Phase 3 study that is actively recruiting participants, run by Pharmacosmos A/S. The registered enrollment target is 120 participants.
The verdict
NCT07473128, a Phase 3 study, is actively recruiting participants, sponsored by Pharmacosmos A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.
Interventions
- DRUG Trilaciclib
- DRUG Saline (0.9% NaCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07473128
The ClinicalTrials.gov registry entry for NCT07473128 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacosmos A/S, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trilaciclib is the first listed.
NCT07473128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07473128 about?
NCT07473128 is a clinical study titled "Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer". The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Pa...
What is the current status of trial NCT07473128?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2026-06-30. Estimated completion is 2027-06.
What interventions are being tested in trial NCT07473128?
The interventions under investigation include: Trilaciclib (DRUG), Saline (0.9% NaCl) (DRUG).
Who is sponsoring clinical trial NCT07473128?
This trial is sponsored by Pharmacosmos A/S, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.